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Objective. To evaluate the safety of the antimicrobial peptide, lactocin 160. Methods. Lactocin 160, a product of vaginal probiotic
Lactobacillus rhamnosus 160 was evaluated for toxicity and irritation. An in vitro human organotypic vaginal-ectocervical tissue
model(EpiVaginal)wasemployedforthesafetytestingbydeterminingtheexposuretimetoreducetissueviabilityto50%(ET-50).
Hemolyticactivityoflactocin160wastestedusing8%ofhumanerythrocytesuspension.Susceptibilityoflactobacillitolactocin160
was also studied. Rabbit vaginal irritation (RVI) model was used for an in vivo safety evaluation. Results. The ET-50 value was 17.5
hours for lactocin 160 (4.9 hours for nonoxynol 9, N9). Hemolytic activity of lactocin 160 was 8.2% (N9 caused total hemolysis).
Lactobacilli resisted to high concentrations of peptide preparation. The RVI model revealed slight vaginal irritation. An average
irritation index grade was evaluated as “none.” Conclusions. Lactocin 160 showed minimal irritation and has a good potential for
intravaginal application.
Copyright © 2007 Sara E. Dover et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Lactobacillus rhamnosus 160 was isolated from the vagi-
nal microﬂora of a healthy female subject. This bacterium
produces the ribosomally synthesized antimicrobial peptide
(bacteriocin) lactocin 160, which is active against the most
prevalent species associated with bacterial vaginosis (BV). Its
bactericidal activity (as shown on model microorganisms) is
duetothedisturbanceofthecellularmembrane,probablyby
pore formation, which leads to eﬄux of ATP [1, 2].
BV is a common condition in women which occurs when
the healthy vaginal bacterial ﬂora, consisting mostly of Lac-
tobacillus species, is replaced by a ﬂora consisting of several
bacterial pathogens [3]. It is associated with pregnancy com-
plications such as premature labor as well as with a higher
risk of acquisition of HIV infection [4–6].
Since lactocin 160 is active against an array of vaginal
bacterial pathogens, it has a potential application as an an-
timicrobial treatment of BV. It is, therefore, important to de-
termine the safety of the bacteriocin for human application.
For in vitro toxicity study, the EpiVaginal tissue model from
MatTek Corporation (Ashland, Mass, USA) was employed.
This model uses human vaginal ectocervical cells, obtained
from healthy adult females, and is free from viral, micro-
bial, and yeast infections. The tissue has a three-dimensional
structure that mimics that of the human vaginal tissue and
the results are highly reproducible, quantiﬁable, and less ex-
pensive compared to in vivo studies [7]. The in vitro data
was compared with rabbit vaginal irritation (RVI) model.
The aim of this study was an in vitro and in vivo testing of
antimicrobial peptide lactocin 160 to determine vaginal tis-
sue toxicity, hemolytic activity, and inhibition of lactobacilli
growth.
2. METHODS
2.1. Productionoflactocin160
Lactobacillusrhamnosusstrain160wasstoredinthebiofreez-
er (−80
◦C) until use. Lactocin 160 was puriﬁed as described
previously [1]. Brieﬂy, L. rhamnosus 160 was grown anaero-
bically overnight in 2000mL MRS (Difco Lactobacilli MRS
broth) at 37
◦C. The cells were harvested by centrifugation
(5100xg,20minutes,4 ◦C),andwashedthreetimesin0.01M2 Infectious Diseases in Obstetrics and Gynecology
phosphate buﬀered saline (PBS, Sigma-Aldrich, Mo, USA).
The pellet was resuspended in 200mL chemically deﬁned
media that resembles vaginal ﬂuid but lacks proteins [8], and
incubated anaerobically at 37
◦Cf o r2 0h o u r sw i t ha g i t a t i o n
(100rpm).
Thesupernatantwasbroughtto80%saturationwitham-
monium sulphate (Sigma-Aldrich). Precipitated (not active)
proteins were removed by centrifugation (11,000 xg, 25 min-
utes, 4◦C). The supernatant was dialyzed against double dis-
tilled water for three days with the molecular weight cutoﬀ
of 1kDa, (Spectra/Por Cellulose ester dialysis membranes,
Spectrum). This was followed by lyophilization to obtain dry
lactocin 160 preparation.
2.2. Proteinconcentration
Lactocin 160 is a partially puriﬁed protein preparation and
contains other high molecular products, with trace amounts
of salts from the medium. Protein concentration was mea-
sured using BCA method (Pierce, Ill, USA) and determined
spectrophotometrically at 562nm.
2.3. Determinationofweakorganicacidpresencein
thepreparation
Prior to the toxicity study, lactocin 160 was resuspended in
double distilled water at a concentration of 200mg/mL. The
samples’ acidity was analyzed by potentiometer (Microcom-
puter pH-vision 6071, Markson, Honolulu, Hawaii, USA)
and the lactic acid concentration was measured using a com-
mercial D- and L-lactic acid testing kit (R-Biopharm AG,
Darmstadt, Germany). The sample was ﬁlter sterilized using
a0 . 4 5µm centrifuge ﬁlter (Millipore Corporation, Billerica,
Mass, USA).
2.4. HPLCandelectrospray-MSanalysis
To determine reproducibility of the composition of the par-
tially puriﬁed lactocin 160 preparations, samples from 3 in-
dependent batches were submitted to Proteomics Resource
Facility (Integrated Biotechnology Laboratories, University
of Georgia, Ga, USA) for HPLC and electrospray-MS anal-
ysis.
2.5. EpiVaginaltissuesmodel
EpiVaginal tissues (VEC-100) were obtained from MatTek
Corporation and placed in the refrigerator at 4◦C until use.
All tissues were used within 24 hours. Prior to application
of the product, tissues were preequilibrated in 6 well plates
(Falcon)with0.9mLofDMEM-basedDC-100MMmedium
(MatTek Corporation). Plates containing tissue culture in-
serts were placed in a humidiﬁed incubator at 37
◦Ca n d
5% CO2 for one hour. Media was removed and replaced by
0.9mLoffreshVEC-100-MMmedium.Then,83µLofpr od-
uct was applied topically on triplicate EpiVaginal (VEC-100)
tissues. For exposure times of greater than 24 hours, tissue
inserts were airlifted by placing them on 2 washers (MatTek
Corporation) and fed with 5mL of the assay medium. Ini-
tial exposure times of lactocin 160 (200mg/mL) were 4, 9,
24, and 48 hours. Distilled water, used as negative control,
was applied to duplicate tissue culture inserts at time points
6, 24, and 48 hours. Spermicide containing 4% Nonoxynol-9
(Ortho Options CONCEPTROL Vaginal Contraceptive Gel,
Advanced Care Products, Skillman, NJ, USA) has a well-
documented cytotoxicity (7, 9, 10), and was therefore chosen
as a positive control. Antifungal cream, containing 4% mi-
conazole nitrate (Monistat-3, Ortho McNeil Pharmaceutical,
Inc., Raritan, NJ, USA), is a nontoxic preparation and was
used as a negative control [7, 9–11].
Tissue viability at the end of the exposure time was de-
termined using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) viability assay. Approximate
eﬀective times (ET) for each product to reduce tissue viabil-
ity to 50% (ET-50) values were calculated, from which new
time points were selected to obtain a more accurate ET-50
value.
2.6. MTTviabilityassay
Viability of cells was determined by measuring the break-
down of the yellow tetrazolium component MTT to purple
formazan following manufacturers’ (MatTek Corporation)
recommendations. As only living cells perform breakdown
of MTT, the reduction is directly proportional to the amount
oflivingcells[12].Brieﬂy,aftercompletionofexposuretimes
of lactocin 160 and positive and negative controls to tissues,
the liquid in the inserts was decanted, followed by washing
the tissue inserts in Dulbeccos phosphate-buﬀered saline so-
lution (D-PBS). Nonliquid test material was removed care-
fully with a sterile polyester ﬁber tipped swab (Thermo-
Fisher, Waltham, Mass, USA). Tissues were then placed in a
24 well plate with 300µL MTT (1.0mg/mL) solution in cul-
turemediumandincubatedfor3hoursat37
◦Cand5%CO2.
Following MTT incubation, the tissue inserts were placed in
a new 24 well plate and immersed in 1.66mL of isopropanol
(MatTekCorporation)toextracttheformazan.Toreduceex-
tractant evaporation, the plate was covered with sealing ﬁlm
(Thermo-Fisher). The plate was incubated overnight in the
dark at room temperature. Upon completion of extraction,
the liquid from the wells was mixed with the liquid from the
inserts. After mixing, 200µL of extractant solution was mea-
sured spectrophotometrically in triplicate at 570nm in a 96
well plate reader (MRX revelation, Dynex Technologies, Va,
USA) using extractant solution as blank.
Tissue viability (%) was determined according to the
manufacturer’s recommendations and using the equation:
%viability = OD570(treated tissue)/OD570(control tissue).
The exposure time that reduced the tissue viability to 50%
wascalculatedasdescribedpreviously[7]byplottingthelog-
arithm of the dosing time versus % viability and then inter-
polating the times near when the viability is 50%. In general,
a shorter ET-50 corresponds to a more irritating/damaging
test article; a longer ET-50 corresponds to milder/less dam-
aging test article.Sara E. Dover et al. 3
2.7. ReductionofMTTbytestpreparations
In order to assure reduction of MTT was not caused by the
test articles, thereby generating incorrect results, reduction
of MTT by each product was measured. This was done by
adding 83µLo fp r o d u c tt o1m Lo fM T Ts o l u t i o na n di n c u -
bating at room temperaturein the dark for 60 minutes. 83µL
ofdoubledistilledwaterin1mLofMTTsolutionwasusedas
negative control. Absence of darkening of solution color in-
dicated that the test article and controls did not reduce MTT.
2.8. Rabbitvaginalmodel
This safety assay was conducted at Euroﬁns Product Safety
Laboratories (Dayton, NJ, USA). This study was performed
to comply with the Good Laboratory Practice (GLP) regula-
tions as deﬁned in: 21 CFR 58: U.S. FDA Good Laboratory
Practice Standards.
A quantity equal to 1.8mL of the test article at pH 6.0,
containing 10mg/mL dissolved in sterile distilled water was
administered intravaginally to six healthy female rabbits.
One dose was administered daily to each animal for ten con-
secutive days. A negative and positive control group, con-
sisting of six female rabbits each, was maintained under the
same environmental conditions and dosed daily with 1.8mL
of sterile distilled water and 4% nonoxynol-9, respectively.
All animals were observed for mortality, signs of gross toxi-
city, and behavioral changes at least once daily for 11 days.
Body weights were recorded prior to administration and on
day 11 (study termination). Individual vaginal irritation was
measured prior to each intravaginal administration and on
day 11. The entire vagina was excised, examined, and scored
for exudates (vaginal discharge); edema; and erythema. The
vagina from each rabbit was ﬁxed and saved in 10% neu-
tral buﬀered formalin. Scores for the vaginal discharge and
edema were: 0—normal/none, 1—slight, 2—moderate, 3—
severe, and scores for erythema were: 0—normal, 1—pink,
2—red, 3—beet red. Necropsies were performed on all ani-
m a l sa tt e rm i n a ls ac ri ﬁ c e .Th r ees ecti o n so ft h ec o l u m n a re p -
itheliumofthevagina(includingcervical,central,andcaudal
portions)wereexaminedmicroscopicallyfromhematoxylin-
and eosin-stained slides. The maximum score for the micro-
scopic evaluation was 16.
2.9. Hemolysisassay
Outdated human blood erythrocytes obtained from the
Blood Center of the Rush University of Chicago (Ill, USA)
were used for the determination of hemolysis. Serial dilu-
tions of lactocin 160 (12.5–200mg/mL) were prepared in
PBS. 100µL aliquots of each dilution were incubated with
1mL of 8% erythrocyte suspension in 1x PBS for 15 min-
utes at 22
◦C, and then centrifuged at 1500rpm for 1 minute.
The absorbance at 405nm of released hemoglobin was mea-
sured spectrophotometrically. Hemolytic activities are pre-
sented as the percentage of the total erythrocytes lysed [13].
Sodium dodecyl sulfate was used as a control for total lysis.
Hemolyticactivityoflactocin160wascomparedto1–4%N9.
Table 1:ET-50valuesofproductsusingtheEpiVaginaltissuemodel
(mean± standard deviation).
Product and active ingredient ET-50 (h)
Lactocin 160 (200mg/mL) 17.45 ±0.35
Spermicide
Nonoxynol 9 (4%) 4.85 ±1.06
Antifungal cream
Miconazole nitrate (4%) 35.6 ±17.5
2.10. Inhibitionofvaginallactobacillus
Theinhibitoryeﬀectoflactocin160onbacterialspecieschar-
acteristic of a healthy vaginal ﬂora was studied against 10
vaginal Lactobacillus species (healthy human subjects iso-
lates) by determining minimum inhibitory concentration
(MIC) using the microdilution method in MRS broth. The
tested range of two-fold dilution of lactocin 160 was 1.5–
200mg/mL with inoculum size of 5 × 105 CFU/mL. Loaded
wellswereoverlaidwithsterilemineraloiltocreateanaerobic
condition for lactobacilli growth. MIC was determined using
Bioscreen reader-incubator (Labsystems, Helsinki, Finland).
3. RESULTS
3.1. Lactocin160preparationanalysis
An amount of 100mg of partially puriﬁed lactocin 160 con-
tained 21.5±1.29µg protein. The test for lactic acid detected
less than 1% L-lactic acid concentration of the dry weight of
three samples of lactocin160; D-lactic acid was found in in-
signiﬁcant amounts. This test conﬁrmed that the activity of
lactocin160 was not caused by lactic acid.
3.2. HPLCandelectrospray-MSanalysis
The HPLC analysis was used to conﬁrm reproducibility of
thepeptiderecoverymethodfromthreeindependentbatches
of lactocin 160. It revealed that the samples have very simi-
larproteinproﬁles(graphsnotshown).Theelectrospray-MS
analysis conﬁrmed the reproducibility data with signiﬁcant
noise due to the presence of amino acids (data not shown).
3.3. ET-50values
The concentration of 200mg/mL of lactocin 160 preparation
was chosen forthe in vitro safetystudy as this higher concen-
tration is more likely to later be used in a commercial prod-
uct. Lactocin 160 at this concentration showed very little ir-
ritation, with an average ET-50 value of 17.5 hours. Table 1
summarizestheET-50valuesforthesamples.Asanexample,
Figure 1 presents the data from one study.
As expected, N9 was most toxic for EpiVaginal cells, with
an average ET-50 value of 4.9 hours. This conﬁrms previous
in vitro and in vivo studies [7, 14, 15]. With an ET-50 value
of >24 hours, miconazole nitrate showed very low toxicity in
our study. This is in accordance with previous in vitro and in
vivo testing using the RVI model and clinical trials [7, 9–11].4 Infectious Diseases in Obstetrics and Gynecology
Table 2: Individual vaginal irritation and histopathology scores. Histopathology scores include evaluation of epithelium, leukocytes inﬁl-
tration, vascular congestion, and edema.
Average score Vaginal discharge/erythema
Histopathology
score (Group
mean)
D a y 23456789 1 0 1 1 11
Distill water (n = 6) 0.0/0.0 0.0/0.0 0.0/0.0 0.0/0.0 0.0/0.0 0.0/0.0 0.0/0.0 0.0/0.0 0.0/0.0 0.0/0.0 5.2
N-9 (n = 6) 0.0/0.0 0.3/0.5 0.3/0.5 0.3/0.7 0.3/0.7 0.8/1.0 1.2/1.0 1.0/1.3 1.7/1.5 1.3/1.3 10.5
Lactocin 160 (n = 6) 0.0/0.0 0.0/0.0 0.0/0.0 0.0/0.2 0.0/0.2 0.0/0.2 0.3/0.3 0.3/0.3 0.3/0.3 0.3/0.3 5.7
Nonoxynol 9 (4%)
Lactocin 160 (200mg/ml)
Miconazole nitrate (4%)
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Figure 1: Lactocin 160 preparation is not toxic for human vaginal
cells as tested in EpiVaginal tissue (VEC-100) model. The presented
data illustrate %viability versus time (hours) for following prepara-
tions: , nonoxynol 9 (4%); •, lactocin 160 (200mg/mL); ,m i -
conazole nitrate (4%).
An increase in liquid was observed in the insert of tissue
exposed to lactocin 160. This might have been due to diﬀer-
ences between products and media, thereby causing water to
enter the tissue insert by osmotic pressure. It may also be due
to bacteriocins inducing EpiVaginal cells to produce mucin.
Astheliquidinthewellswasnotviscous,theﬁrstspeculation
is more likely to have account for the observation (personal
communication with Dr. Ayehunie at MatTek Corp.).
3.4. ReductionofMTTbytestarticle
MTT was not reduced to formazan by lactocin 160, micron-
azole nitrate, or nonoxynol 9. Thus, reduction of MTT was
only performed by viable cells, and not caused by test article.
This conﬁrms the validity of the assay.
3.5. Rabbitsafetyassay
All animals survived, gained body weight, and appeared ac-
tive and healthy during the study. In control group with
4% N9 apart from a red gelatinous substance in the pan-
line noted for one animal on day 2, there were no other signs
of gross toxicity, adverse pharmacologic eﬀects, or abnormal
behavior(Table 3).Slight-to-moderatevaginaldischargeand
pink-to-rederythemawerenotedforalltreatedsitesbetween
days 3 and 11. No gross abnormalities were noted for any
of the animals when necropsied at the conclusion of the 11-
day observation period. Slight vaginal discharge, pink-to-red
erythema, and/or slight-to-moderate edema were observed
in all six rabbits at time of necropsy. The positive for irrita-
tion control tissues (nonoxynol-9 treatment) were given an
average irritation index grade of “mild.”
In the test group (lactocin 160 treatment), slight vaginal
discharge and/or pink erythema were noted for three treated
sites between days 5 and 11. No gross abnormalities were
noted for any of the animals when necropsied at the con-
clusionofthe11-dayobservationperiod.Slight-to-moderate
vaginal discharge, pink-to-red erythema, and/or slight-to-
moderate edema were observed in all six rabbits at time of
necropsy. The test tissues for lactocin 160 were given an av-
erage irritation index grade of “none.” Under the conditions
of this test, the lactocin 160 did not produce any signiﬁcant
vaginal irritation.
3.6. Toxicityforlactobacilli
Lactocin 160 preparation’s MIC for the tested 10 vaginal Lac-
tobacillus spp was >200mg/mL.
3.7. Hemolyticactivity
Table 3 presents data of human erythrocyte hemolysis by lac-
tocin 160 (12.5–200mg/mL) and N9. The range of observed
hemolysis was 1.2 ± 0.34–8.2 ± 0.6%. In fact, N9 in concen-
tration 1–4% caused total hemolysis of erythrocytes.
4. DISCUSSION
Lactocin 160, an antimicrobial peptide produced by Lacto-
bacillus rhamnosus, did not show any severe irritation in the
RVI model, ectovaginal tissue, hemolytic activity, or vaginal
lactobacilli inhibition. The ET-50 values of the lactocin 160
preparations were similar or less than over-the-counter non-
toxicproducts.Ourtoxicitystudiesrevealedthatlactocin160
can be considered safe for human use.
For vaginal toxicity studies, thein vivo RVI model has
been the preferred choice for a long time. This model deter-
mines the cervicovaginal irritation as minimal, mild, mod-
erate, and severe based on a scoring system evaluating ep-
ithelial ulceration, leucocytic inﬁltration, edema, and vascu-
lar injection [16]. As it is an established standard, the results
c a nb ec o m p a r e dt oo t h e rp r o d u c t s[ 17–19]. The RVI modelSara E. Dover et al. 5
Table 3: Hemolytic activity of lactocin 160.
Substance Lactocin 160 (mg/mL) N9 (%)
Concentration 200 100 50 25 12.5 1–4
Hemolytic activity (% of control) 8.2 ±0.66 .2 ±0.24 .1 ± 0.28 1.1 ±0.34 0 100
is, however, best for identifying agents that will cause severe
irritation[20]. This model poses some shortcomings, mainly
because of the diﬀerence in vaginal tissue between rabbit and
human. Also, extra variables have to be taken into account,
for example, the physical status, the health history of the
rabbit, and the immune system. The RVI model approach
proved not to be totally reliable in the case of the spermicidal
agent nonoxynol 9. This commonly used contraceptive was
determined to be suitable for human use in the rabbit irrita-
tion model; but with frequent use it induces inﬂammatory
reactions and disruption of the vaginal epithelia [14, 15].
This has possible adverse eﬀects including higher risk of ac-
quisition of HIV [21]. In addition, prolonged exposure (10
days in diﬀerent concentrations) to N9 in the rabbit vagina
revealedsevereinﬂammatorychangesincludingerosionsand
loss of epithelial lining. The damage was proportional to the
amount of N9 used [22].
In vitro models for vaginal irritation include monolayers
of cells, which have been used for many years to determine
safety, for example, endocervical vaginal epithelial HeLa-S3
cells [23] and immortalized human vaginal and cervical ep-
ithelial cells [24–26]. However, monolayer cultures are not
optimalforirritationstudiesastheydonotaccuratelyresem-
ble three-dimensional, diﬀerentiated vaginal tissue and also
have diﬀerent gene and protein expression [7].
Three-dimensional models of normal ectocervicovaginal
epithelial cells, grown on polycarbonate ﬁlters, have previ-
ously been used. In a study of the pokeweed antiviral pro-
tein microbicide, no correlation was found between the re-
sults of the in vitro and the RVI model, the latter being much
more sensitive [18]. These researchers hypothesized that this
mightbeduetotheinvitrosystemlackingthedynamicsofin
vivo testing. The inﬂammation may have been caused by the
product’s eﬀect on mast cells, thereby creating the inﬂamma-
tory reaction instead of a direct cytotoxic eﬀect to the vaginal
epithelial cells.
In this study, we sought to transition from the traditional
in vivo vaginal irritation test to a reliable and reproducible in
vitro vaginal model. We chose EpiVaginal model because it
is a three-dimensional organotypic ectocervicovaginal tissue
that was reconstructed using normal, well-stratiﬁed epithe-
lialcells,containingdiﬀerentiatedbasal,suprabasal,interme-
diate, and superﬁcial cell layers similar to in vivo tissue. The
in vivo and in vitro results were similar and revealed little or
notoxicityoflactocin160.Thisinvitromodeliscost-eﬀective
and can be considered as an alternative to the animal model.
To the best of our knowledge, this is the ﬁrst in vitro
vaginal irritation study of a bacteriocin from a vaginal pro-
biotic Lactobacillus strain using EpiVaginal tissues. Vaginal
safety was studied for the bacteriocin nisin. This well-known
bacteriocin is widely used for food preservation but is not
produced by any vaginal isolates [23, 27]. Nisin has been
proposed as a contraceptive agent even though it kills the
healthy vaginal microﬂora consisting of Lactobacillus species
inconcentrationsmuchlowerthantheonesproposedforthe
nisin’s spermicidal application (our unpublished data). The
absence of vaginal irritation of nisin in rat and rabbit model
was conﬁrmed in vitro using endocervical vaginal epithe-
lial HeLa-S3 cells measuring viability [23, 28]. Also, nisin’s
hemolytic activity has been studied well. It was found that
nisin caused hemolysis of sheep erythrocytes at concentra-
tions that were 1000-fold higher than those required for an-
timicrobial activity [29].
Documenting the antimicrobial activity against vaginal
lactobacilli is an important concern for vaginal formula-
tion safety study. For instance, it was shown that presence
of nonoxinol-9 aﬀects the ecological balance of the vagina
by inhibiting the protector lactobacilli [30–32]. At the same
time, our in vitro and in vivo toxicity studies showed that
the antimicrobial peptide lactocin 160 produced by vaginal
L. rhamnosus did not irritate vaginal epithelial tissue, and it
was not hemolytic for human erythrocytes or toxic for vagi-
nal lactobacilli. These results suggest that it would be safe in
formulations to treat bacterial vaginosis.
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